يعرض 1 - 20 نتائج من 1,879 نتيجة بحث عن '"NordForsk"', وقت الاستعلام: 0.67s تنقيح النتائج
  1. 1
    Report

    المساهمون: Mats Heyman, MD, Associate Professor

    المصدر: A Treatment Study Protocol of the ALLTogether Consortium for Infants, Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL): a Pilot Study
    Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, Klausen TW, Jonsson OG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Frandsen TL, Marquart HV, Madsen HO, Noren-Nystrom U, Schmiegelow K. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18.
    Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3.
    Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poiree M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cave H, Rohrlich P, Bertrand Y, Benoit Y; Children-s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC). Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.
    Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7.
    Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6.

  2. 2
    Report

    المساهمون: Mats Heyman, MD, Associate Professor

    المصدر: ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
    Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, Klausen TW, Jonsson OG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Frandsen TL, Marquart HV, Madsen HO, Noren-Nystrom U, Schmiegelow K. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18.
    Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3.
    Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poiree M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cave H, Rohrlich P, Bertrand Y, Benoit Y; Children-s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC). Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.
    Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7.
    Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6.
    Toksvang LN, Als-Nielsen B, Bacon C, Bertasiute R, Duarte X, Escherich G, Helgadottir EA, Johannsdottir IR, Jonsson OG, Kozlowski P, Langenskjold C, Lepik K, Niinimaki R, Overgaard UM, Punab M, Raty R, Segers H, van der Sluis I, Smith OP, Strullu M, Vaitkeviciene G, Wik HS, Heyman M, Schmiegelow K. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol. BMC Cancer. 2022 May 2;22(1):483. doi: 10.1186/s12885-022-09522-3.

  3. 3
    Report

    المصدر: The Use of Worktime Planning Tools in the Finnish Public Sector. A Quasi-experimental Study (PLANTOOLS)
    Ala-Mursula L, Vahtera J, Kivimaki M, Kevin MV, Pentti J. Employee control over working times: associations with subjective health and sickness absences. J Epidemiol Community Health. 2002 Apr;56(4):272-8. doi: 10.1136/jech.56.4.272.
    Des Jarlais DC, Lyles C, Crepaz N; TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004 Mar;94(3):361-6. doi: 10.2105/ajph.94.3.361.
    Goldberg D, Williams P. 1988. A user´s guide to the General Health Questionnaire. Berkshire: UK. NFER-Nelson.
    Hansen AM, Nabe-Nielsen K, Albertsen K, Hogh A, Lund H, Hvid H, Garde AH. Self-rostering and psychosocial work factors - a mixed methods intervention study. Appl Ergon. 2015 Mar;47:203-10. doi: 10.1016/j.apergo.2014.10.006. Epub 2014 Oct 22.
    Harma M, Ropponen A, Hakola T, Koskinen A, Vanttola P, Puttonen S, Sallinen M, Salo P, Oksanen T, Pentti J, Vahtera J, Kivimaki M. Developing register-based measures for assessment of working time patterns for epidemiologic studies. Scand J Work Environ Health. 2015 May 1;41(3):268-79. doi: 10.5271/sjweh.3492. Epub 2015 Mar 19.
    Idler EL, Angel RJ. Self-rated health and mortality in the NHANES-I Epidemiologic Follow-up Study. Am J Public Health. 1990 Apr;80(4):446-52. doi: 10.2105/ajph.80.4.446.
    OARS. 1978. Multidimensional functional assessment: The OARS methodology (2nd ed.). Durham, NC: Duke University.
    Turunen J, Karhula K, Ropponen A, Koskinen A, Hakola T, Puttonen S, Hamalainen K, Pehkonen J, Harma M. The effects of using participatory working time scheduling software on sickness absence: A difference-in-differences study. Int J Nurs Stud. 2020 Dec;112:103716. doi: 10.1016/j.ijnurstu.2020.103716. Epub 2020 Jul 14.
    Karhula K, Turunen J, Hakola T, Ojajarvi A, Puttonen S, Ropponen A, Kivimaki M, Harma M. The effects of using participatory working time scheduling software on working hour characteristics and wellbeing: A quasi-experimental study of irregular shift work. Int J Nurs Stud. 2020 Dec;112:103696. doi: 10.1016/j.ijnurstu.2020.103696. Epub 2020 Jun 24.
    Shiri R, Karhula K, Turunen J, Koskinen A, Ropponen A, Ervasti J, Kivimaki M, Harma M. The Effect of Using Participatory Working Time Scheduling Software on Employee Well-Being and Workability: A Cohort Study Analysed as a Pseudo-Experiment. Healthcare (Basel). 2021 Oct 16;9(10):1385. doi: 10.3390/healthcare9101385.
    Karhula K, Hakola T, Koskinen A, Lallukka T, Ojajarvi A, Puttonen S, Oksanen T, Rahkonen O, Ropponen A, Harma M. Ageing shift workers' sleep and working-hour characteristics after implementing ergonomic shift-scheduling rules. J Sleep Res. 2021 Aug;30(4):e13227. doi: 10.1111/jsr.13227. Epub 2020 Nov 9.
    Turunen J, Karhula K, Ropponen A, Koskinen A, Shiri R, Sallinen M, Ervasti J, Pehkonen J, Harma M. The Time-Varying Effect of Participatory Shift Scheduling on Working Hour Characteristics and Sickness Absence: Evidence from a Quasi-Experiment in Hospitals. Int J Environ Res Public Health. 2022 Nov 8;19(22):14654. doi: 10.3390/ijerph192214654.

  4. 4
    Report
  5. 5
    Report

    المصدر: Cognitive Behavioral Therapy for Insomnia Among Different Types of Shift Workers
    Jarnefelt H, Harma M, Sallinen M, Virkkala J, Paajanen T, Martimo KP, Hublin C. Cognitive behavioural therapy interventions for insomnia among shift workers: RCT in an occupational health setting. Int Arch Occup Environ Health. 2020 Jul;93(5):535-550. doi: 10.1007/s00420-019-01504-6. Epub 2019 Dec 18. Erratum In: Int Arch Occup Environ Health. 2020 Jul;93(5):551. doi: 10.1007/s00420-020-01527-4.

  6. 6
    Report
  7. 7
  8. 8
    Report
  9. 9
    Report
  10. 10
    Report
  11. 11
    Report
  12. 12
    Report
  13. 13
  14. 14
    Electronic Resource
  15. 15
  16. 16
    Report
  17. 17
    Electronic Resource
  18. 18
    Electronic Resource

    المؤلفون: NordForsk, Academy of Finland, Canadian Institutes of Health Research, Lady Davis Institute, Canada Foundation for Innovation, Cancer Research UK, National Institutes of Health (US), Genome Canada, Japan Society for the Promotion of Science, European Commission, Medical Research Council (UK), National Institute for Health Research (UK), Wellcome Trust, German Research Foundation, Federal Ministry of Education and Research (Germany), Instituto de Salud Carlos III, Junta de Andalucía, Columbia University, Università degli Studi di Siena, Ministero della Salute, Consejo Superior de Investigaciones Científicas (España), Swedish Research Council, Technical University of Munich, University of Helsinki, Nakanishi, Tomoko [0000-0001-9510-5646], Pigazzini, Sara [0000-0002-0641-9393], Cordioli, Mattia [0000-0002-4872-0520], Butler-Laporte, Guillaume [0000-0001-5388-0396], Maya-Miles, Douglas [0000-0002-0669-6526], Nafria Jimenez, Beatriz [0000-0002-4698-5680], Bouysran, Youssef [0000-0003-1368-6550], Niemi, Mari [0000-0003-0696-6175], Palom, Adriana [0000-0002-0130-1302], Ellinghaus, David [0000-0002-4332-6110], Khan, Atlas [0000-0002-6651-2725], Martínez-Bueno, Manuel [0000-0002-4333-4487], Roade, Luisa [0000-0002-8160-9613], Fava, Francesca [0000-0002-4363-2353], Spinner, Christoph D. [0000-0002-3875-5367], Prati, Daniele [0000-0002-2281-7498], Bernardo, David [0000-0002-2843-6696], Darcis, Gilles [0000-0001-8192-1351], Fernández-Cadenas, Israel [0000-0003-4821-2363], Holter, Jan Cato [0000-0003-1618-5022], Frithiof, Robert [0000-0003-2278-7951], Kiryluk, Krzysztof [0000-0002-5047-6715], Duga, Stefano [0000-0003-3457-1410], Asselta, Rosanna [0000-0001-5351-0619], Pereira, Alexandre [0000-0002-7782-5540], Romero-Gómez, Manuel [0000-0001-8494-8947], Hov, Johannes R. [0000-0002-5900-8096], Migeotte, Isabelle [0000-0002-8972-8211], Renieri, Alessandra [0000-0002-0846-9220], Planas, Anna M. [0000-0002-6147-1880], Ludwig, Kerstin [0000-0002-8541-2519], Buti, María [0000-0002-0732-3078], Rahmouni, Souad [0000-0003-0956-0242], Alarcón-Riquelme, M. E. [0000-0002-7632-4154], Schulte, Eva C. [0000-0003-3105-5672], Karlsen, Tom H. [0000-0002-8289-9931], Valenti, Luca [0000-0001-8909-0345], Zeberg, Hugo [0000-0001-7118-1249], Richards, Brent [0000-0002-3746-9086], Ganna, Andrea [0000-0002-8147-240X], Nakanishi, Tomoko, Pigazzini, Sara, Degenhardt, Frauke, Cordioli, Mattia, Butler-Laporte, Guillaume, Maya-Miles, Douglas, Nafría-Jiménez, Beatriz, Bouysran, Youssef, Niemi, Mari, Palom, Adriana, Ellinghaus, David, Khan, Atlas, Martínez-Bueno, Manuel, Rolker, Selina, Amitano, Sara, Roade, Luisa, FinnGen, The COVID-19 Host Genetics Initiative, Fava, Francesca, Spinner, Christoph D., Prati, Daniele, Bernardo, David, García, Federico, Darcis, Gilles, Fernández-Cadenas, Israel, Holter, Jan Cato, Banales, Jesús M., Frithiof, Robert, Kiryluk, Krzysztof, Duga, Stefano, Asselta, Rosanna, Pereira, Alexandre, Romero-Gómez, Manuel, Bujanda, Luis, Hov, Johannes R., Migeotte, Isabelle, Renieri, Alessandra, Planas, Anna M., Ludwig, Kerstin, Buti, María, Rahmouni, Souad, Alarcón-Riquelme, Marta E., Schulte, Eva C., Franke, Andre, Karlsen, Tom H., Valenti, Luca, Zeberg, Hugo, Richards, Brent, Ganna, Andrea

    مصطلحات الفهرس: preprint

  19. 19
    Electronic Resource
  20. 20
    Electronic Resource